Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
May 01, 2024 08:05 ET
|
Tevogen Bio Inc
For full year 2023, the operating expenses for Tevogen Bio Inc were $8.8 million.
electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024
May 01, 2024 08:04 ET
|
electroCore, Inc.
ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
Form 8.3 - Alpha Financial Markets Consulting plc
May 01, 2024 08:04 ET
|
Octopus Investments
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY...
Radiation-Tolerant PolarFire® SoC FPGAs Offer Low Power, Zero Configuration Upsets, RISC-V Architecture for Space Applications
May 01, 2024 08:02 ET
|
Microchip Technology Inc.
The first real-time Linux® capable, RISC-V-based microprocessor subsystem on a flight-proven RT PolarFire FPGA fabric.
Goodness Growth Provides CREAM & Fire Updates
May 01, 2024 08:01 ET
|
Goodness Growth Holdings, Inc.
– Josh Rosen to shed Interim title and become Chief Executive Officer; Company provides other key personnel updates – – Company receives a short-term extension of the maturity date on its credit...
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
May 01, 2024 08:01 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today...
Recursion to Participate in Upcoming Investor Conferences
May 01, 2024 08:01 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
May 01, 2024 08:00 ET
|
Peak Bio, Inc.
Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in...
Locafy Reports Fiscal Third Quarter 2024 Results
May 01, 2024 08:00 ET
|
Locafy Limited
Company Striving Towards Near-Term Profitability Following Go-to-Market Approach Revamp and Cost Reduction Initiatives New Pay-Per-Click SEO Pricing Model Gaining Strong Traction in Multiple Market...
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
May 01, 2024 08:00 ET
|
Supernus Pharmaceuticals, Inc.
Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree®The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled...